Progyny (NASDAQ:PGNY) Stock: Insider Peter Anevski Sells 236,630 Shares

Progyny, Inc. (NASDAQ:PGNY) CEO Peter Anevski sold 236,630 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $35.84, for a total value of $8,480,819.20. Following the transaction, the chief executive officer directly owned 710,972 shares in the company, valued at $25,481,236.48. This trade represents a 24.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Anevski also recently made the following trade(s):

• On Thursday, November 5th, Peter Anevski sold 11,939 shares of Progyny stock. The stock was sold at an average price of $35.13, for a total value of $419,417.07.
• On Monday, November 9th, Peter Anevski sold 161,308 shares of Progyny stock. The stock was sold at an average price of $35.73, for a total value of $5,763,534.84.

Progyny Trading Down 1.1%

Shares of PGNY stock opened at $36.18 on Friday. The company’s 50-day moving average price is $28.48 and its 200-day moving average price is $24.87. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 33.19, a PEG ratio of 1.70 and a beta of 0.97. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $37.15.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.82%. Progyny’s revenue was up 8.9% compared to the same quarter last year. During the same period last year, the business earned $0.15 earnings per share. As a group, equities research analysts predict that Progyny, Inc. will post 1.41 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on PGNY shares. Canaccord Genuity Group set a $35.00 target price on Progyny in a research note on Friday, August 7th. Truist Financial upped their price target on Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. BTIG Research raised their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Finally, Wells Fargo & Company boosted their price objective on shares of Progyny from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 5th. Eleven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.33.

Institutional Investors Weigh In On Progyny

Several institutional investors and hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new position in Progyny in the 2nd quarter valued at about $29,000. Nykredit A S acquired a new stake in shares of Progyny during the second quarter worth about $38,000. IFP Advisors Inc lifted its position in shares of Progyny by 376.0% during the second quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after purchasing an additional 1,549 shares in the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Progyny in the second quarter valued at approximately $65,000. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Progyny in the second quarter valued at approximately $74,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.